Open AccessClinical effectiveness of reamberin in treating outpatients with chronic obstructive pulmonary disease
Author(s) -
O Yu Lakotsenina,
Л Н Войт,
Emma Sokolova,
M A Grankina
Publication year - 2014
Publication title -
kazanskij medicinskij žurnal
Language(s) - English
Resource type - Journals
eISSN - 2587-9359
pISSN - 0368-4814
DOI - 10.17816/kmj1983
Subject(s) - medicine , pulmonary function testing , anesthesia , cardiology
Aim. To investigate the clinical effectiveness of meglumine sodium succinate in treating patients with chronic obstructive pulmonary disease in an outpatient setting.Methods. 93 patients with chronic obstructive pulmonary disease were examined. The influence of 3-month combined treatment with long-acting M-anticholinergic drug (tiotropium bromide), combination of salmeterol and fluticasone (Seretide) and antihypoxant drug - meglumine sodium succinate (Reamberin) in combination with breathing exercises on functional parameters of respiratory, cardiovascular system and quality of life was studied.Results. Signs of deceased pulmonary ventilation due to obstruction were revealed. Pulmonary hypertension and decreased right ventricle diastolic function were diagnosed in 89% of patients. Patients taking meglumine sodium succinate (Reamberin) showed statistically significant improvement of functional indices of respiratory and cardiovascular systems, as well as better quality of life after the treatment. In patients who were not taking meglumine sodium succinate, those changes were less prominent.Conclusion. Adding meglumine sodium succinate (Reamberin) to complex treatment of patients with chronic obstructive pulmonary disease supports the improvement in pulmonary function and macrocirculation, which demonstrates the improvement of pulmonary gas exchange function and improves quality of life.